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Advances in imaging techniques (CT and MRI) and widespread use of imaging especially ultrasound scanning have resulted in
a dramatic increase in the detection of small renal masses. While open partial nephrectomy is still the reference standard for
the management of these small renal masses, its associated morbidity has encouraged clinicians to exploit the advancements in
minimally invasive ablative techniques. The last decade has seen the rapid development of laparoscopic partial nephrectomy and
novel ablative techniques such as, radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation
(CA). In particular, CA for small renal masses has gained popularity as it combines nephron-sparing surgery with a minimally
invasive approach. Studies with up to 5-year followup have shown an overall and cancer-speciﬁc 5-year survival of 82% and 100%,
respectively. This manuscript will focus on the principles and clinical applications of cryoablation of small renal masses, with
detailed review of relevant literature.
Copyright © 2008 J. L. Dominguez-Escrig et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Worldwide, around 208500 new cases of renal cancer are
diagnosed each year, accounting for just under a 2% of all
cancers with higher incidence in more developed countries
[1–3]. Regardless of its true impact on annual incidence,
the widespread use of more sensitive imaging techniques
(USS, CT, and MRI) has led to an increase in the number of
incidentally detected renal tumors [4–7], with an estimated
increased detection of asymptomatic, small renal masses by
60% in recent years [8].
InEurope,themostrecentestimatesofincidenceofrenal
cancer suggest that there are 63300 new cases annually in
the EU25, accounting for nearly 3% of all cancers [9], with
an estimated annual increase in incidence of approximately
2% [2, 10]. In Spain, the estimated incidence and mortality
for the year 2002 were 4085 (2778 men, 1307 women) and
1644 (1093 men, 551 women) cases, respectively (FCAECC,
La situacion del cancer en Espa˜ na. Ministerio de Sanidad,
2005).
In contrast to a historical incidence of 5% of renal
tumours of less than 3cm in size, current incidence of such
tumours ranges between 10% and 40% [11, 12]. Although
the natural history and biological behaviour of this “small
renal mass” are yet to be understood, the available evidence
demonstrates a rather slow growth of these small masses,
with an annual size increase not greater of 0.5cm [13–17].
Furthermore, between 15% and 30% of small renal tumours
a r ec o n ﬁ r m e dt ob eb e n i g no rt oh a v eal o wg r a d ea n dl o w -
malignant potential on pathological examination [18–21].
As a result, urologists now face a subset of early-
stage asymptomatic patients with clinical, pathological, and
morbid characteristics clearly diﬀerent from those with a
classically presented renal malignancy. The management of
this group of patients, while still controversial, has evolved
dramatically in recent years. Conservative approach by
means of active monitoring or watchful waiting has been
advocated by some authors [14, 22–24], and is a feasible
option particularly in the elderly and signiﬁcantly comorbid
patient. Surgery, however, is the preferred management
option for the younger, healthier patient. In recent years,
nephron-sparing surgery (open and laparoscopic partial
nephrectomy) has become the standard treatment for small
renalmasses,withdataavailablefromlargeseriesconﬁrming
similar5-yearcancer-speciﬁcsurvivalrates(90%–100%)and
a low risk (0%–3%) of local recurrence [25–29]. Although2 Advances in Urology
laparoscopic partial nephrectomy has clear advantages over
the open approach, particularly on wound-related mor-
bidity, its technical diﬃculty has limited its widespread
use. Consequently, laparoscopic and percutaneous ablative
techniques in renal surgery, such as, radio frequency abla-
tion (RFA), high-intensity focused ultrasound (HIFU), and
cryoablation (CA) are being increasingly utilized as they
oﬀer parenchymal preservation along with less morbidity.
Although long-term oncological data is currently not avail-
able, present 5-year followup data is very encouraging. This
article will focus on cryoablation (CA) of small renal masses
and in particular, on laparoscopic cryoablation (LCA), with
an up-to-date review of the available literature and detailed
analysis of the largest published series.
2. HISTORICAL BACKGROUND
Cryoablation has been used in medicine since James Arnott,
back in 1845–1851, demonstrated that freezing temperatures
could be applied to cause tissue destruction [30]. Further
interests in this ﬁeld with improved delivery system and
understanding of freeze-thaw sequence were followed by the
use of CA in the treatment of prostate cancer only to be
abandoned because of local complications [31–34].
Attheturnofthelastcentury,drivenbytheneedformin-
imallyinvasivetechniquesandfacilitatedbyrapidtechnolog-
ical developments, a renewed interest on cryoablation and its
applications in urological oncology re-emerged. Experience
with vacuum-insulated liquid nitrogen or argon-cooled
probes in other disciplines and technological advantages
in intraoperative imaging [35], laparoscopic USS probes in
particular, has allowed a safe and eﬃcient targeting of kidney
tumours. As a result, renal cryoablation, either percutaneous
or laparoscopic, has become a feasible and exciting new
minimally invasive surgical option for the treatment of small
masses.
3. CRYOBIOLOGY AND PATHOPHYSIOLOGY
OF CRYOABLATION
Cryoablation causes tissue destruction by a direct, as well as
by a vascular, delayed mechanism [36, 37]. Direct cell dam-
age begins with falling temperatures as structural/functional
cell components are stressed and cell metabolism progres-
sively fails. With freezing, ice crystal formation ﬁrst occurs in
theextracellularspace,creating ahyperosmotic environment
which draws water from the cells and, by a “solution-
eﬀect injury,” causes cell shrinkage and membrane damage.
With further cooling, especially at high cooling rates, ice
crystals will form within the cell. This phenomenon, pos-
sibly facilitated by cell-to-cell propagation via intercellular
channels [38], is almost always lethal to the cell. While
some cells will contain ice crystals at temperatures as high
as −15◦C, certainty of intracellular ice formation requires
temperatures below −40◦C (homogeneous nucleation) [37,
39]. During thawing, with temperatures above −40◦C,
ice crystals fuse into larger crystals (“recrystallization”)
which, together with a transient hypotonic extracellular
environment that draws water back into the cell, will result
in further damage of the cell membrane and membrane
rupture.
Indirectly,hypoxicdamageoccursasaresultofmicrovas-
cularstasis.Withloweringtemperatures,initialvasoconstric-
tion produces a decrease in blood ﬂow, with complete cessa-
tion during freezing. During thawing, the circulation returns
with transient vasodilatation. Endothelial damage produces
increased permeability, oedema, platelet aggregation, and
formation of thrombi, resulting in a sustained microvascular
occlusion and stagnation [40, 41].
While downregulation of tumour suppressor genes es-
sential to the control of apoptosis has been implicated in
most malignancies and proapoptotic factors such as hypo-
thermia, ischaemia, inﬂammation, elevated calcium lev-
els, immunologic-based mechanisms including macrophage
recruitment are associated with freezing injury. Recent
studies implicate gene regulated cell death (apoptosis) in
cryosurgical outcomes [42, 43].
The histological end result is a conﬂuent coagulative
necrosis, as evidenced by the presence of numerous histio-
cytes,cholesterolcrystals,anddystrophiccalciﬁcationwithin
the cryolesion, with eventual ﬁbrosis and scarring. Features
that have been demonstrated in animal models [44, 45]a s
well as in human renal cryoablated tumours [46, 47].
4. TECHNICAL PRINCIPLES OF CRYOABLATION
Renal cryoablation has been shown to produce predictable
and reproducible tissue destruction in animal models [48–
53]. Cell damage depends on the cooling rate, the number
of freeze-thaw cycles [45], the lowest temperatures achieved
as well as the hold time at subzero temperatures [37,
54]. Importantly, while temperature below −19.4◦Ch a s
been shown to be suﬃcient for complete destruction of
normal renal parenchyma [48], neoplastic cells may require
temperatures as low as −50◦C to guarantee cell death [37].
Moreover, preclinical models have demonstrated that such
low temperatures can only be achieved within a core volume
of tissue, limited to 4 to 6mm inside the edge of the forming
ice ball [48, 49]. Thus, most authors will extend the ice ball
to 1cm beyond the tumour margins, incorporating the outer
few millimetres or “indeterminate zone” and a margin of
normal renal parenchyma, to optimize oncological control
[55].
Modern cryoprobes can achieve temperatures as low as
−190◦C by exploiting the Joule-Thompson eﬀect. Typically,
compressed argon gas is allowed to expand through a small
oriﬁce, producing temperatures well below those required to
ablate normal renal tissue (−19.4◦C) [48] and cancer cells
(−40◦C), as demonstrated on in vivo prostatic [56]a n d
renal cryolesions [45]. Although, the number of cycles is still
controversial, early data from in vivo experiments [37]h a s
now been corroborated in cryoablated tumours. With the
incorporation of double-freeze cycles, a larger cryolesion can
be achieved than with a single cycle. Apart of the number of
cycles and in contrast to original experimental observations,
ithasbeendemonstratedthatrapidthawing,withheliumgas
at 15◦Ct o2 0 ◦C/min, does not infringe on lesion size, while
reducing procedural time [45].J. L. Dominguez-Escrig et al. 3
5. CLINICAL APPLICATION OF RENAL CRYOABLATION
Following the ﬁrst experimental renal cryosurgery by
Lutzeyer et al. [57, 58], it was not until 1995 that Uchida et
al.performedtheﬁrstreportedpercutaneouscryoablationin
canine kidneys and, later that year, reproduced the technique
in 2 patients with advanced renal carcinoma [59]. CA has
developed rapidly since and can currently be delivered via
open, laparoscopic and percutaneous approaches.
6. OPEN CA
Feasibility of open renal cryotherapy in humans was ﬁrst
reportedin1996byDelworthetal.,attheUniversityofTexas
M. D. Anderson Cancer Center, after a successful treatment
of two patients with tumours in a solitary kidney, one renal
cell carcinoma and one angiomyolipoma [60]. Rukstalis et
al. published in 2001 the ﬁrst report on systematic use of this
approach [61]. A total of 29 tumours (22 solid masses and
7 complex cysts) with a median size of 2.2cm were treated
using intraoperative ultrasound monitoring and double-
freeze sequences. With a median followup of 16 months,
only one patient had a biopsy-conﬁrmed recurrent tumour.
Five serious adverse events occurred in 5 patients, with only
one event directly related to the procedure. Overall, 91.3%
of patients demonstrated a complete radiographic response
[61]. In 2002, Khorsandi et al. reported open cryoablation
on 17 patients with small renal tumours (median 2cm;
range: 1.1–4.2cm), using a double freeze-thaw technique to
−180◦C. Median age was 62 years (range: 35–75 years). With
a median followup of 30 months (range: 10–60 months),
MRI demonstrated infarction and a reduction of lesion size
in 15 of 16 cases. One patient’s mass was unchanged at 3
months followup [62].
Whilst open CA oﬀers safe parenchymal preservation,
wound morbidity appears to be the drawback of this
technique. With only two further reports in the literature
[63, 64], practice in recent years has clearly favoured the
laparoscopic and percutaneous approaches, with a marked
trend towards the former.
7. LAPAROSCOPICCA(LCA)
Laparoscopic cryoablation (LCA) oﬀers several procedural
advantages, namely, a minimally invasive approach, mag-
niﬁcation, direct visualization of the tumour and internal
manipulation of the cryoprobes and dual (visual and ultra-
sound) monitoring of the cryolesion [65]a sw e l la sa l l o w i n g
extensive pathologic sampling [66]. Surgeon preference and
experience are crucial for choosing between transperitoneal
and retroperineoscopic approaches. While transperitoneal
approach allows a more direct access to anterior tumours,
it carries a higher risk of bowel injury. Posteriorly located
tumours are more amenable to retroperineoscopy, however,
blunt dissection in this approach is associated with an
increased risk of bleeding [12].
In our experience at Sunderland Royal Hospital, from
September 2005, 17 patients have undergone LCA under
a strict departmental protocol. Patient is positioned in
Figure 1: Ultrasound scanning of an exophytic left renal tumour
exposed by laparoscopic mobilisation prior to cryoablation.
lateral position as for nephrectomy. We used one 10mm
port for camera and two working ports (10 and 5mm).
Depending on the position of the tumour, we have used a
further 5mm port to retract the liver. Following adequate
pneumoperitoneum, kidney is mobilised in order to access
the tumour favourably for the needle insertion and for
ultrasound probe positioning. Gerota’s fascia and peri-renal
fat are carefully dissected to expose the tumour. A standard
biopsy of the tumour is then performed. Cryoprobes (17G)
are inserted under visual and ultrasound control (Figure 1),
at a maximum distance of 1cm apart from each other.
Tumour core temperature and tumour margin temperature
are monitored throughout. Our protocol includes 2 Freeze-
Thaw cycles: Freezing, during 10 minutes, achieving a core
temperature of −70◦C and a peripheral temperature of
at least −40◦C, followed by of 10 minutes of thawing (5
minutes active + 5 minutes passive thawing). The ice-
ball is monitored visually by the surgeon and by real-time
laparoscopic USS probe (Hitachi) performed by an expert
consultant uroradiologist (Figure 2). The ice-ball is extended
to a minimum of 5mm beyond the tumour margins.
Following surgery, our preferred imaging modality is pre-
and postcontrast CT, which is performed as part of our
followup protocol at 3, 6, 12, 18, 24 and yearly thereafter.
Renal function is checked at each clinic visit. Since majority
of recurrences are found at 3 months and almost all at 1 year,
CT or MRI at 3, 6, 12 months and yearly thereafter has been
recommended by other authors [67].
No treatment failures have been so far observed. Twelve
masses (70%) were demonstrated to be a RCC. Histology
in one patient revealed urothelial carcinoma necessitating
nephroureterectomy. One patient required transfusion and
anotherunderwentembolisationofanarterio-venousﬁstula.
A comprehensive review of the literature reveals promis-
ing results. A summary of outcomes for the larger series is
summarised in Table 1.
In 2003, Lee et al. reported results of LCA with
ultrasound guidance, double-freeze cycle and up to 3-years
followup (mean 20.25 months), in 20 patients with small4 Advances in Urology
Figure 2: Visualisation of the Ice-ball during thawing, demon-
strating arrangement of cryoprobes and temperature monitoring
probes.
renal masses (1.4–4.5cm) and age ranging from 43 to 84
years. Mean operating time was 305.9 minutes and blood
loss 92.5mL (50–200mL). Biopsies demonstrated renal cell
carcinoma (RCC) in 11 cases, none of which had recurred.
Overall survival was 100% for this cohort [68].
In the same year, Nadler et al. reported results on 15
patients. Meanagewas68.5 years(range: 49–86 years).Mean
tumour size was 2.15cm (range: 1.2–3.2cm), and mean
estimated blood loss was 67mL (range: 15–125mL). RCC
wasdemonstratedin10cases.Medianradiographicfollowup
(15 months, range 4.9–27 months) revealed stable lesions in
all patients. There was 1 treatment failure due to incomplete
treatment of the periphery of the lesion. Another patient,
with a successfully treated tumour, had a positive followup
biopsy due to multifocal papillary renal cell carcinoma and
required nephrectomy [69].
Initial data from the Southern Illinois University was
published in 2005, a total of 25 patients with an average
age of 65 years (range: 32–83 years) and mean tumour
size of 2.4cm (range: 1.5–3.6cm). Pathology revealed RCC
in 72% of cases. With a followup for up to 36 months
(range: 6–36 months), no recurrences were reported [70].
Subsequent publication including 84 consecutive patients
with an average age of 67 years and a mean tumour size
of 2.6cm (range: 1.2-4.7cm) of which, 70 procedures were
performed laparoscopically. They reported 7 conversions, 2
of them for failures. Intraoperative biopsy yielded a 59%
malignancyrate.Withameanfollowupof10months(range:
3–36 months), an abnormal postoperative enhancement
occurred in 2 patients, one of which was conﬁrmed to be a
RCC [71].
Cestari et al. presented data from a cohort of 70 patients
treated with laparoscopic (48 transperitoneal, 28 retroperi-
neoscopic) cryoablation (LCA). Average age was 63.2 years,
mean size 2.37cm (range: 1–6cm), mean operating time and
blood loss were 181.4 minutes and 164.2mL, respectively.
With a followup of up to 36 months, progressive reduction
of the cryolesion was demonstrated in all patients on MRI.
Only 1 patient required radical nephrectomy for recurrent
tumour [72].
In 2005, with 168 cases performed at the Cleveland
Clinic Foundation (1997–2005), Hegarty et al. reported,
prospectivelycollected,intermediate-term(3years)followup
data in 56 patients, with a mean tumour size of 2.3cm, who
underwent LCA under a strict MRI imaging and CT-guided
biopsy followup protocol, introduced in 1997. Sequential
mean cryolesion size on MRI on postoperative 1 day, at 3
and 6 months, and at 1, 2, and 3 years was 3.7, 2.8, 2.3, 1.7,
1.2, and 0.9cm, representing a 26%, 39%, 56%, 69%, and
7 5 %r e d u c t i o ni nc r y o l e s i o ns i z ea t3a n d6m o n t h sa n d1 ,
2, and 3 years, respectively. At 3 years, 17 cryolesions (38%)
had completely disappeared on MRI. Postoperative needle
biopsy identiﬁed locally persistent/recurrent renal tumour
in 2 patients. In the 51 patients undergoing cryotherapy for
a unilateral, sporadic renal tumour 3-year cancer speciﬁc
survival was 98%. There was no open conversion. During
the 2006 AUA Meeting, this group presented updated results
on 60 patients that had each completed 5 years followup
(median 72 months). Mean tumour size was 2.3cm (range
1–4.5cm).Threepatients(6.7%)developedlocalrecurrence.
Overall and cancer-speciﬁc 5-year survival was 82% and
100%, respectively [73].
Moon et al. published results on 16 patients with
small renal masses (mean size 2.6cm), and their mean
operating time was 188 minutes. There was 1 reported
conversion, and mean blood loss was 40mL. Tumour biopsy
demonstrated 5 RCC. With a mean followup of 9.6 months,
all tumours remained nonenhancing and either stable or
smaller than the original lesion [74]. This group has recently
reported combined data from its 5-year experience with
renal cryoablation on 88 cases, treated by LCA [58]o rP C A
[20]. Mean tumour size was 2.6cm. At a mean followup of
19 months, the overall, cancer-speciﬁc and recurrence-free
survival rates were 88.5%, 100%, and 98.7%, respectively.
Four patients required a further treatment due to persistent
disease, and one had progression to locally advanced disease
[75].
In 2007 Polascik et al. published results from his
experience in 26 patients who underwent LCA using third-
generation cryotechnology, for 28 renal masses of 3.5cm or
less (median 2cm). Patients were followed by serial CT or
MRI scan, at least every six months after cryoablation. The
mean patient age was 64 years (range: 44–79), and the mean
followup was 20.9 months. The median tumour size was
2.0cm (range: 1–3.5cm). No patient was converted to open
surgery. With an overall survival rate of 100%, no evidence
of recurrence or progression was found in this cohort [76].
With 47 cases in their series, Beemster et al., from the
University of Amsterdam group, have now published data on
26 patients with available followup of 6 months or more.
With an average followup of 17.2 months (range: 6–36
months) and a mean tumour size of 2.4cm (range: 1.3–
3.8cm), only 1 treatment failure has been reported [77].
In agreement with data generated by larger series,
preliminary results from smaller series have recently been
published [78–81]. Although comprising smaller number of
patients and limited followup in some cases, the publishedJ. L. Dominguez-Escrig et al. 5
Table 1: Summary of largest reported series on LCA.
n Age,
years
Follow-
up,
months
Tumour diameter,
cm
%o f
RCC
Failures/
Recurrences
Operative
time, min.
Hospital
stay, days Complications
Lee et al. [68] 20 67.9
(43–84)
20.3
(1–40) 2.6 (1.4–4.5) 55% 1/0 305.9 2.6
Atrial ﬁbrilation (1),
ECG changes, no MI
(1), Pancreatic injury
(1), transient raised
lipase-amylase (5),
Transfusion (1)
Nadler et al.
[69] 15 68.5
(49–86)
15
(4.9–27) 2.15 (1.2–3.2) 67% 1/1 3.5
Respiratory failure
(1), prolonged ileus
(1)
Schwartz et al.§
[71] 70 67
(32–85) 10 (3–36) 2.6 (1.2–4.7) 59% 1/1 2.2
CVA (1), transfusion
(2), renal fracture (1),
Transient
hydronephrosis (1)
Cestari et al.
[72] 70 63.2 36
(28–48) 2.37 (1–6) 69% 0/1 181.4 4.5
Haematuria (2),
pyrexia (6), bleeding
(1), Anaemia (6),
Pulmonar oedema
(1), PUJ Obstruction
Hegarty et al.
[73] 60 72 2.3 (1–4.5) 0/3 174.2 2.4
2% transfusion rate.
Congestive Heart
Failure (1), Splenic
haematoma (1),
oesophagitis (1),
Pleural eﬀusion (1)
Moon et al.
[74] 16 9.6
(1–28) 2.6 (1.5–3.5) 33% 0/0 188 1.9 Pneumonia (1)
Polascik et al.
[76] 26 64
(44–79)
20.9
(2–53) 2.5 (1–3.5) 0/0 2 (0–9)∗ Transfusion (1),
prolonged ileus (1)
Beemster et al.
[77] 26 17.2
(6–36) 2.4 (1.3–3.8) 1/0 Paraesthesia (1), UTI
(1), pneumonia
n: Number of patients.
RCC: Renal cell carcinomas found on histology.
Values expressed as mean unless stated otherwise.
§Total of 84 cases in this series. Only 70 of them were performed laparoscopically.
∗Value expressed as median.
series clearly demonstrate the increasing interest and rapid
expansion of this novel ablative technique.
8. PERCUTANEOUS CRYOABLATION (PCA)
While technical limitations hampered initial attempts at
percutaneous cryoablation in human kidneys [59], the rapid
development of argon technology and ultrathin probes,
together with CT and open access interventional MRI,
allowing real-time monitoring of the ice ball, provided the
muchneededtechnicalbreakthroughs,makingthisapproach
safe and reproducible.
In 2001, Shingleton and Sewell [82] reported their initial
experience in 20 patients (22 tumours) treated with 2 or
3mm cryoprobes and interventional MRI. Mean tumour
size was 3cm (range: 1.8–7cm), and average treatment
time was 97 minutes (range: 56–172 minutes). Procedures
were performed under general anaesthesia or sedation, and
95% of patients were discharged within 24 hours. With a
mean followup of 9.1 months (range: 3–14 months), they
reported only one failure, requiring retreatment. The only
complication was a superﬁcial wound abscess. Recently, the
authorshaveupdated their seriesincluding patients with von
Hipple-Lindau [83] and with tumour/s in a solitary kidney
[84]. With an average followup of 24 months, 9 (15%) cases
requiredretreatmentduetoincompleteinitialablation.Only
1 patient required transfusion, and there were no reported
cancer-related deaths.
Experience on 23 patients (26 tumours) with mean size
2.6cm (range: 1–4.6cm) and mean age of 66 years (range:
43–86 years) was reported by Silverman et al., using a 0.5-
T open MR imaging system and general anesthesia. Twenty
four masses were RCCs, 1 was an urothelial carcinoma
and 1 was an angiomyolipoma. With a mean followup
of 14 months (range: 4–30 months), 24/26 tumours were
successfullyablated,23ofwhichrequiredonlyonetreatment
session. In 2 cases, a small enhancing nodule located at the
margin proved to be recurrent tumours. Two complications6 Advances in Urology
(1 haemorrhage requiring transfusion and 1 abscess drained
percutaneously) occurred in a total of 27 cryoablations [85].
In 2006 Gupta et al. published CT-guided PCA on 27
tumours of 5cm or less (mean size 2.5cm), using conscious
sedation and real-time CT monitoring. With 1 month or
more followup imaging available on 16 cases (mean 5.9
months), 15 tumours showed no signs of enhancement. In
1 case, blood transfusion was required for bleeding [86].
The Mayo Clinic experience on 40 cases of PCA with
CT monitoring has recently been published [87]. Mean
tumour size was 4.2cm (range: 3.0–7.2cm) and at least 3
months followup was available in 65% of the cases (mean
9 months; range: 3–22 months). Technical success, deﬁned
as extension of the ice ball beyond the tumour margin and
absence of postablation enhancement on CT, was reported
in38(95%)cases,withnotumourrecurrenceorprogression
in the cohort. Overall complication rate for this cohort was
reported at 8%.
9. FUTURE DIRECTIONS
Initial studies of combination therapy with 5-FU prior
to freezing, indicated a temperature-dependent reduction
on cell viability in a prostate cancer cell (PC-3) model
[88]. Furthermore, molecular analysis using this model has
demonstrated a synergistic eﬀect of sublethal concentrations
of 5-FU and Cisplatin prior to freezing (−15◦C), mediated
by a shift in the Bcl-2 to Bax ratio to a prodeath tendency
[89]. Similar synergistic response has been reported in a
renalcellmodel,thedatasuggestingthat5-FUchemotherapy
m a yb em o r ee ﬀective when followed by cryosurgery [90]. In
the clinical setting, synergistic activity of cryoablation and
cyclophosphamide is currently been evaluated on advanced
epithelial tumours (NCI. Trial protocol NCT00499733).
Equally, since freezing enhances the radiosentitivity of
cells, combination of radiotherapy with cryoablation may
potentially confer beneﬁts [65], as already indicated in pre-
clinical models of prostate cancer, where adjuvant radiation
and curcumin have demonstrated a synergistic eﬀect with
cryoablation [91].
At the time of writing this review, the Cleveland Clinic
group have made public the initial results employing Single
Port Access Renal Cryoablation (SPARC). A total of 6
patients, with mean tumour size of 2.6 ±0.4cm, successfully
underwent SPARC, via a transperitoneal or retroperitoneal
approach, with no intraoperative complications and no need
for conversion, demonstrating the feasibility and safety of
this, potentially scarless, procedure [92, 93].
Further development of imaging techniques and cry-
oprobe technology, clinical evaluation of combination ther-
apy with conventional chemo- and radiotherapy, together
with promising novel cryoenhancers, may have major impli-
cations on the management of small renal masses in the
future
10. CONCLUSIONS
Widespread implementation of USS, CT, and MRI has
resultedinanincreaseddetectionofearly,smallrenalmasses.
In the last 20 years, the proportion of incidentally found
renal tumours raised from 13% to an estimated 60%, with
a substantial parallel decrease in tumour stage, grade, and
proportion of metastasis at presentation, in these patients
[94]. As a result, urologists are now faced with a new cohort
of asymptomatic, healthier patients, with incidentally found
small renal masses.
While open partial nephrectomy is still the reference
standard [95], its associated morbidity has encouraged
researchers and practicing clinicians towards less radical
approaches, thus the rapid development of laparoscopic
partial nephrectomy and novel ablative techniques such
as radiofrequency ablation (RFA), high-intensity focused
ultrasound (HIFU), and cryoablation (CA). Among abla-
tive techniques, cryotherapy, and in particular laparoscopic
cryoablation,isthemostextensivelystudiedandtheonewith
more rapid expansion in clinical practice.
Cryosurgery oﬀers the clear advantage of combining a
nephron-sparing surgery together with a minimally invasive
approach. Anaesthetic requirements, postoperative analge-
sia, and hospital stay are signiﬁcantly reduced, with a much
rapid return to normal activity and work.
In the early days of development and clinical imple-
mentation of cryoablation, concerns were raised regarding
safety of the procedure, the lack of followup, and oncological
outcome [96].
Regarding the safety of the procedure, published studies
up to this day have shown minimal procedure-speciﬁc mor-
bidity, with complication rates comparable or better than
current available minimally invasive procedures. Reports
from the largest series have demonstrated to be a less morbid
procedure than laparoscopic partial nephrectomy, with a
comparable 5-year oncological safety [97].
Among the novel ablative techniques, radio frequency
ablation(RFA)istheprocedureswithmoreemergingclinical
data. Although the procedure-speciﬁc morbidity, mostly
basedonsmallandnonstandardisedseries,appearstobelow,
serious issues have been raised regarding the RFA cell-killing
potential and its higher risk of local disease recurrence, as
demonstrated en several clinical studies [98–102].
When compared to RFA, available data from preclinical
[52] and several clinical studies confer to cryoablation
an advantageous oncological safety proﬁle. The Cleveland
Clinic group have recently published results from their RFA
and LCA series, highlighting the issue of residual disease
and demonstrating a clear advantage in the LCA cohort.
With 109 renal lesions (88 patients) treated with RFA and
192 lesions (176 patients) treated with LCA, radiographic
(CT or MRI) success at 6 months was 85% and 90% for
RFA and LCA, respectively. More importantly, when lesions
were later biopsied at 6 months, the success in the RFA
cohort decreased to 64.8%, while LCA success remained
high at 93.8%. Six of 13 patients (46.2%) with a 6-month
positive biopsy after radio frequency ablation demonstrated
no enhancement on posttreatment MRI or CT, while in
the LCA group, all positive biopsies revealed posttreatment
enhancement on imaging just before biopsy. The authors
recommend postradio frequency ablation followup biopsyJ. L. Dominguez-Escrig et al. 7
duetothesigniﬁcantriskofresidualrenalcellcancerwithout
radiographic evidence [103].
Supporting these ﬁndings, a recent meta-analysis of
available data demonstrates a higher risk of local disease
recurrence in tumours treated with RFA, when compared to
those managed by cryoablation [104].
While long-term followup is still awaited, encouraging
results have been reported in series with up to 5-year
followup, with cancer-speciﬁc survival rates ranging from
98 to 100% [68, 70, 72, 73, 76, 105] with LCA and 97%
with PCA [7]. This is comparable to 5-year cancer-speciﬁc
survival rate of 92%, reported with partial nephrectomy
[95, 97, 106].
Whileclinicalapplicationandindicationsofcryoablation
of small renal masses are still not clearly deﬁned, it is
recommended by available clinical evidence, that CA should
be reserved for small (<3cm) solid-enhancing renal masses
in older patients with high operative risk. Young age, tumour
size >4cm, hilar tumours, intrarenal tumours, and cystic
lesions can be regarded as relative contraindication, whilst
irreversible coagulopathy is widely accepted as an absolute
contraindication [107].
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